LILyluma Ishfaq

Lyluma Ishfaq

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lyluma Ishfaq has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Systematic Review on NSAID and Tanezumab efficacy in Chronic Lower Back Pain

    by Smaran Kasireddy, Sweta Sahu, Lyluma Ishfaq, Berjis Rahmath, Navya Pillikunte Doddareddy, Mudit Moondra, Mihirkumar P. Parmar, Vishal Venugopal

    Chronic back pain is an ailment that impacts people of all ages and lasts longer than 12 weeks. 7.41% of all Years Lost to Disability (YLD) are associated with low back pain, which makes it the pathology responsible for the most YLD, surpassing other chronic conditions such as Diabetes and Depression. Despite the prevalence of drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs), painkillers, and biologics, the types of drugs administered to individuals differ greatly. We collected data from the PubMed database of the PubMed database, National Library of Medicine (NIH), and Google Scholar. Randomized controlled trials (RCTs) that explicitly evaluate the effectiveness of various NSAIDs in adult patients with chronic back pain were selected for this study. After an exhaustive search and examination of numerous publications, only 8 articles met the inclusion criteria. In recent studies that included NSAIDs, they were among the most frequently prescribed medications for the treatment of chronic low back pain. In comparison to placebo, selective COX-II inhibitors such as celecoxib and etoricoxib were found to be efficacious, while valdecoxib was associated with serious side effects. In addition to reducing back pain, COX-II inhibitors with a preference for COX-II, such as aceclofenac and diclofenac, were associated with gastrointestinal side effects. Despite the risk of joint degeneration and accelerated osteoarthritis, intravenous tanezumab may be superior to naproxen and placebo in treating chronic low back pain.

  • Open Access

    Impact of Proton Pump Inhibitors on Kidney Function and Chronic Kidney Disease Progression: A Systematic Review

    by Mihirkumar P. Parmar, Safa Kaleem, Periyaiyadever Samuganathan, Lyluma Ishfaq, Anne Sai Nitya Tejaswi, Yashaswi Patel, Bollu Sashank Sai, Vishal Venugopal

    Aim: The aim of this systematic review is to comprehensively assess and analyze the impact of proton pump inhibitors on kidney function and their potential role in the progression of chronic kidney disease. Through a meticulous examination of available literature, we aim to provide a clear understanding of the relationship between proton pump inhibitor use and kidney health, shedding light on potential risks, benefits, and contributing factors. Ultimately, this research aims to inform healthcare professionals and patients alike about the implications of proton pump inhibitors on kidney function, facilitate informed medical decisions, and improve patient care. Methods: We used the following medical subject headings (MeSH) terms with keywords like "irritable bowel syndrome" and "kidney injury" to gather data from the National Library of Medicine (PubMed), PubMed Central (PMC), and Google Scholar. Articles from the last 10 years, 2013 to 2023, were gathered for this systematic review. Results: The results indicate a complex relationship between proton pump inhibitors and kidney function, as well as the progression of chronic kidney disease. Conclusion: In the end, this systematic review shows that there is a link between long-term use of proton pump inhibitors and a higher risk of kidney problems. Patients and healthcare providers should weigh the benefits of proton pump inhibitor therapy against potential risks, especially in individuals with pre-existing kidney conditions, and consider alternative treatment options when appropriate. Regular monitoring of kidney function in proton pump inhibitor users may also be advisable to ensure early detection and management of any adverse effects.